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Abstract The agr quorum-sensing system in Staphylococci
controls the production of surface proteins and exoproteins. In
the pathogenic species Staphylococcus aureus, these proteins
include many virulence factors. The extracellular signal of the
quorum-sensing system is a thiolactone-containing peptide
pheromone, whose sequence varies among the different staphy-
lococcal strains. We demonstrate that a synthetic Staphylococ-
cus epidermidis pheromone is a competent inhibitor of the
Staphylococcus aureus agr system. Derivatives of the phero-
mone, in which the N-terminus or the cyclic bond structure was
changed, were synthesized and their biological activity was
determined. The presence of a correct N-terminus and a
thiolactone were absolute prerequisites for an agr-activating
effect in S. epidermidis, whereas inhibition of the S. aureus agr
system was less dependent on the original structure. Our results
show that effective quorum-sensing blockers that suppress the
expression of virulence factors in S. aureus can be designed based
on the S. epidermidis pheromone.
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1. Introduction
Bacteria have the ability to signal and sense the state of
population density in order to respond to changing physio-
logical needs under di¡erent growth conditions. This phenom-
enon is commonly called quorum-sensing [1]. Recently, the
systems involved in quorum-sensing of Gram-negative and
Gram-positive bacteria have been proposed as promising tar-
gets for anti-microbial therapy. In pathogenic bacteria, many
of the extracellular virulence factors are regulated by such
systems. Unlike conventional antibiotics, drugs interfering
with quorum-sensing systems would have the advantage of
speci¢cally suppressing the expression of virulence factors
without killing the bacteria, thus minimizing the selection
for resistant strains [2].
Staphylococcus aureus is a pathogen which can cause seri-
ous, severe infections such as endocarditis, septicemia, pneu-
monia and toxic shock syndrome [3]. Furthermore, it is the
primary cause of nosocomial infections. There is an urgent
need for new e¡ective antibiotics against S. aureus since
most clinical strains are now multi-resistant. Appearance of
intermediate vancomycin-resistance in S. aureus has already
been observed in the USA and in Japan [4,5] and there are no
further antibiotics for the treatment of multi-resistant Staph-
ylococci.
Many virulence factors of S. aureus, including K-toxin, L-
toxin, N-toxin, serine protease, DNase, ¢brinolysin, enterotox-
in B and toxic shock syndrome toxin-1, are controlled by the
agr system [6]. The agr locus of S. aureus, about 3.5 kb in size,
comprises the agrA, agrC, agrD and agrB genes, which are co-
transcribed (forming the mRNA RNAII), and the gene for a
regulatory RNA molecule, RNAIII. The RNAIII DNA re-
gion also encodes the gene for the N-toxin (hld). RNAIII con-
trols the expression of target genes by an unknown mecha-
nism. The agr genes are transcribed from the P2 promoter and
the RNAIII molecule is synthesized from the P3 promoter [7].
The roles of AgrB and AgrD have recently become more
clear. A small peptide is excized from the AgrD protein, modi-
¢ed and secreted as the agr pheromone peptide into the sur-
rounding medium. This peptide represents the autoinductive
signal of the agr system. The pheromone activates the AgrC/
AgrA two-component regulatory system that in turn activates
transcription of the agrBDCA and RNAIII genes [8,9]. The
staphylococcal agr pheromone peptides contain an intramo-
lecular thiolester between a conserved central cysteine and the
C-terminal carboxy group. We have demonstrated this for the
pheromone peptide of Staphylococcus epidermidis [10]. AgrB
seems to be involved in the maturation and secretion process
of the modi¢ed peptide.
Here, we report on the biological e¡ects of the S. epidermi-
dis agr pheromone. Derivatives of the pheromone were syn-
thesized to evaluate the in£uence of changes at the N-terminus
and of the bond type in the cyclic structure. We show that the
S. epidermidis pheromone is a potent inhibitor of the S. aureus
agr system and of the agr-controlled expression of virulence
factors in S. aureus. By derivatization of the pheromone, we
were able to construct a compound that inhibits the S. aureus
agr system as well as the natural pheromone, but does not
activate the S. epidermidis agr system.
2. Materials and methods
2.1. Bacterial strains
S. epidermidis Tu«3298 (DSM 3095 [11]) was the wild-type test strain
and the host for the promoter test plasmid pRB594P3. S. aureus
strains tested for N-toxin production were S. aureus Newman
(NCTC 8178), 8325-4 (derived from NCTC 8325, [12]), SA113
(ATCC 35556: derived from NCTC 8325), ATCC 12600, RN4220
(derived from 8325-4, [13]), ATCC 33591 and three further strains
from our collection (60/055, 6538, 502A). S. aureus RN6390 [14] is a
prototypic strain from which the following mutant strains are derived:
S. aureus RN6911 (‘agr3’) is an isogenic mutant carrying an agr: :
getM mutation, ‘sar3’ (strain ACL 136) carries a sar: :Tn917LTV1
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mutation and ‘agr3/sar3’ (strain ACL 135) carries both a sar: :
Tn917LTV1 and an agr: :tetM mutation [15].
2.2. Plasmids
The promoter test plasmid pRB594 is a derivative of pRB373 [16].
It contains the promoterless pUB112 cat gene [17] adjacent to a multi-
ple cloning site and carries the erythromycin-resistance gene ermB
from transposon Tn551. Plasmid pRB594P3 was constructed by in-
sertion of a BamHI-digested PCR product of the agr P3 region of S.
epidermidis ATCC 14990 into the BamHI site of the multiple cloning
site [10].
2.3. General methods
S. epidermidis cells were grown in TSB or BM (‘basic medium’: 1%
tryptone (Difco), 0.5% yeast extract (Gibco BRL), 0.5% NaCl, 0.1%
K2HPO4, 0.1% glucose). Staphylococcal cells were disrupted in 20 mM
Tris-HCl (pH 7.8) by glass beads as described [18]. Cell debris were
removed by centrifugation (10 min, 5000Ug). Membrane fractions
were prepared by additional ultracentrifugation of the crude cell ex-
tract at 105 000Ug for 1 h. Surface-associated proteins were isolated
by boiling cells at 100‡C for 5 min and centrifugation (10 min,
5000Ug). Surface proteins were isolated by incubating cells with ly-
sostaphin for 10 min at 37‡C and centrifugation (10 min, 5000Ug).
Chromosomal staphylococcal DNA was prepared according to the
method of Mamur [19].
Proteins were separated by tricine-SDS-PAGE according to Scha«g-
ger and von Jagow [20] using Bio-Rad Protean IIxi chambers and a
separation length of 16 cm.
2.4. DNA sequence analysis
DNA was sequenced by cycle sequencing on a DNA sequencer 4000
L (LI-COR, Lincoln, NE, USA) using the Thermo Sequenase £uo-
rescent-labelled prime cycle sequencing kit (Amersham, Little Chal-
font, UK). All £uorescent-labelled primers were purchased from
MWG-Biotech (Ebersberg, Germany).
2.5. Electrospray mass spectrometry (ESI-MS)
ESI-MS was performed on an API III TAGA Triple Quadrupole
(Perkin Elmer Sciex, Thornhill, Ont., Canada). Samples were dis-
solved in acetonitrile/water (1:1, v/v) and introduced into the ion
source at a constant £ow rate of 70 Wl/min. The ori¢ce voltage was
set at 80 V.
2.6. Preparative and analytical high performance liquid
chromatography (HPLC)
Crude peptides were isolated on a Waters 600 Multi Solvent Deliv-
ery System equipped with a Lambda Max Model 481 as detector. A
semi-preparative column (Nucleosil C18, 4U250 mm; 5 Wm; Grom,
Herrenberg, Germany) was eluted at a £ow rate of 3.5 ml/min with a
linear gradient (10^100% B in A in 45 min; solvent A: 0.1% tri£uoro-
acetic acid (TFA) in water; solvent B: 0.1% TFA in acetonitrile). The
detection wavelength was 214 nm.
The concentration of puri¢ed peptides, redissolved in dimethylsulf-
oxide (DMSO), was determined using analytical HPLC on a Kontron
HPLC system with Kroma System 2000 software. An analytical col-
umn (Spherisorb ODS2 2U100 mm; 5 Wm; Grom, Herrenberg, Ger-
many) was eluted at a £ow rate of 250 Wl/min with a linear gradient
(0^100% B in A in 30 min; solvent A: 0.1% TFA in water; solvent B:
0.1% TFA in acetonitrile). The detection wavelength was 214 nm. A
known amount of the (unmodi¢ed) peptide DSVCASYF was used as
a reference.
The amount of N-toxin was quanti¢ed using the same system. A
Pharmacia Resource PHE 1 ml column was eluted with 1.5 column
volumes of a linear gradient (0^100% of B in A; A: 0.1% TFA in
water; B: 0.1% TFA in acetonitrile). The S. epidermidis N-toxin was
eluted using the same conditions on an Aº KTA explorer 100 system
(Amersham Pharmacia Biotech, Freiburg, Germany). The isolated
N-toxin was chemically analyzed by ESI-MS.
2.7. Synthesis of peptides
Peptides were synthesized using the Fmoc/tBu strategy on Trityl-
resin (PepChem: Clausen and Goldammer, Tu«bingen, Germany). The
sequence of the peptide was DSVXASYF, with cysteine (C), serine (S)
or 1,3-diaminopropionic acid (Dpr) in the X position. The corre-
sponding protected amino acids for the synthesis of cyclic peptides
were Fmoc-Cys(Mmt)-OH, Fmoc-Ser(Trt)-OH (both cleavable with
TFA:TIS in dichloromethane [21]) and Fmoc-Dpr(Dde)-OH (cleav-
able with hydrazine [22]). The cyclic peptides were synthesized and
puri¢ed according to Otto et al. [10]. The purity of peptides (s 90%)
was controlled by RP-C18 chromatography and ESI-MS.
2.8. Chloramphenicol acetyltransferase (CAT) assay
CAT activity was determined according to the method of Shaw [23].
The assay mixture contained 100 mM Tris-HCl (pH 7.8), 0.1 mM
acetyl-coenzyme A and 0.4 mg 5,5P-dithiobis-2-nitrobenzoic acid
(DTNB)/ml. Assays were performed in 96 well microtiter plates using
a SpectraMax 340 microtiter plate reader (Molecular Devices, Sunny-
vale, CA, USA) with SpectraMaxPro software. Cell extract (5 Wl) and
5 mM chloramphenicol in 100% ethanol (5 Wl) (or 5 Wl 100% ethanol
in controls) were added to 90 Wl of the assay mixture. Cell extracts
were diluted 1:10 or 1:100 with 20 mM Tris-HCl (pH 7.8) when
necessary. Absorption at 412 nm was measured every 15 s for 20
min. The linear part of the resulting curve was used to determine
the CAT activity (absorption coe⁄cient O= 13 600 l/M for DTNB).
For calculation of the speci¢c activity, protein contents of the cell
extracts were determined using the Bio-Rad DC protein assay for
detergent-containing samples (Bio-Rad Laboratories GmbH, Munich,
Germany).
2.9. Immunoblots
SDS-polyacrylamide gels were blotted onto nitrocellulose mem-
branes (Schleicher and Schuell BA 83) using the semi-dry blotting
technique. Blots were blocked overnight with 5% skim milk. The ¢rst
antibody was applied for 2 h at a concentration of 1:20 000 (anti-K-
toxin) or 1:40 000 (anti-protein A). After washing, the blots were
incubated with anti-IgG-coupled HRP from Amersham Pharmacia
(1:5000) for 1 h. All dilutions were made in Tris-bu¡ered saline
(TBS: 10 mM Tris-HCl, pH 7.4, 150 mM NaCl). Signals were de-
tected with the ECL detection system (Amersham Pharmacia Biotech,
Freiburg, Germany).
2.10. Test of synergistic hemolysis
Blood plates were prepared with sheep blood agar base (Oxoid) to
which 5% de¢brinated sheep blood was added. Samples were spotted
onto ¢lters, which were dried and then laid on agar plates and incu-
bated at 37‡C for at least 24 h.
3. Results
3.1. Synthesis and activity of S. epidermidis pheromone
derivatives
We investigated the biological activity of the S. epidermidis
agr pheromone. Previously, we have demonstrated that it con-
tains an intramolecular thiolester between the central cysteine
and the C-terminal carboxy group within the primary se-
quence DSVCASYF [10]. We have also previously shown
that the derivatives a and b, which represent peptides that
are shortened or elongated, respectively, by one amino acid
of the N-terminal linear peptidyl tail, and which are derived
from the sequence of the AgrD prepeptide, do not activate the
S. epidermidis agr system (for structural representation of the
derivatives see Fig. 1), [10].
To investigate the in£uence of the thiolactone bond on the
biological activity of the pheromone peptide, the following
derivatives of the peptide were synthesized. The strategy was
to substitute the cysteine by serine (Ser) or Dpr. The original
pheromone peptide (compound cS) was stable under acidic
conditions [10]. However, the peptide was more sensitive to
an elevated pH and the ring opened. The serine lactone pep-
tide (compound cO) derivative was extremely sensitive to nu-
cleophiles and electrophiles, which caused the ring to open. In
contrast, the amide bond of the Dpr derivative (compound
cNH) resulted in a signi¢cantly stabilized cyclic peptide. Like
the N-terminal derivatives, the lactone and lactam derivatives
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also were not able to activate the S. epidermidis agr system
(data not shown), which was demonstrated by their failure to
activate CAT expression in our promoter test vector, which
contains the S. epidermidis agr P3 promoter cloned in front of
the cat gene [10] and which is activated in response to extra-
cellularly present pheromone via the AgrC/AgrA two-compo-
nent system.
These results show that the activation of the agr system,
which is mediated by the interaction of the agr pheromone
and the AgrC sensor kinase is extremely speci¢c and depend-
ent on a correct N-terminus and a thiolactone structure.
3.2. Linear derivatives
Balaban et al. [24] puri¢ed an octapeptide from the super-
natant of an S. aureus mutant strain. The octapeptide con-
tained an unresolved amino acid at a position corresponding
to that of cysteine in the agr pheromone peptide. These au-
thors demonstrated that a synthetic peptide containing a tryp-
tophan residue at this position inhibits the agr system of S.
aureus. We therefore speculated that Balaban et al. had orig-
inally puri¢ed a mutated pheromone (from a mutant strain)
and that the introduced tryptophan side chain could substi-
tute for the thiolactone structure. To determine whether the
side chain of another amino acid in the center of the S. epi-
dermidis pheromone peptide could simulate a ring structure
and lead to restored biological activity, we exchanged the
central cysteine of the S. epidermidis pheromone peptide for
every classic proteinogenic amino acid. We have previously
shown that a ring structure is necessary for biological activity
[10]. However, only the linear peptide with the central cysteine
and without the thiolester bridge has been used as a control.
None of the linear peptides synthesized had any e¡ect on the
agr system in our tests, neither an activating e¡ect on S.
epidermidis nor an inhibiting e¡ect on S. aureus (data not
shown).
3.3. Inhibition of the S. aureus agr system
We tested the S. epidermidis pheromone for its activity on
the S. aureus agr system. The e¡ect on the S. aureus agr
system was determined by HPLC measurement of the N-toxin,
which is the translation product of a part of RNAIII. A
Resource PHE column and a water/acetonitrile gradient al-
lowed many samples to be passed through without the column
becoming blocked and o¡ered the advantage that most pro-
teins and peptides passed through the column, whereas the
extremely amphiphilic K-helical N-toxin eluted as a distinct
Fig. 1. Structures of the compounds used in this study. (a) Thiolactone-containing S. epidermidis pheromone harboring an additional glycine at
the N-terminus (compound a); (b) thiolactone-containing S. epidermidis pheromone lacking the original aspartate residue at the N-terminus
(compound b); (c) S. epidermidis pheromone with the original thiolactone structure (-S-, compound cS), replaced by a lactone (-O-, compound
cO) or a lactam (-NH-, compound cNH).
Fig. 2. Concentration-dependent suppression of N-toxin production
in S. aureus Newman by the addition of synthetic S. epidermidis
pheromone or one of its derivatives. Media were inoculated with a
1/100 volume of an overnight preculture of S. aureus Newman. At
the same time, the S. epidermidis pheromone or one of its deriva-
tives was added at the given concentration. The peptides were dis-
solved in DMSO, the control received only DMSO. After 8 h of
growth, the amount of N-toxin produced was determined by HPLC.
The optical density (578 nm) at the harvest time was 2.9 for all cul-
tures. Abbreviations of the compounds refer to Fig. 1.
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peak. Using the supernatant of the S. epidermidis test strain
Tu«3298, this peak was identi¢ed as the N-toxin by mass spec-
trometry and by testing for synergistic hemolysis (data not
shown).
The HPLC N-toxin assay was used to screen ¢rst for S.
aureus strains that produced N-toxin, which indicates that
the agr system is active in these strains. The N-toxin-negative
strain S. aureus RN4220 was used as a control. Of eight
strains tested, four produced N-toxin (strains S. aureus 60/
055, Newman, 8325-4 and ATCC 33591). DNA sequencing
of agrD showed that the pheromone peptide of each of the
positive strains belonged to the S. aureus agr pheromone sub-
group I (pheromone peptide sequence: YSTCDFIM). For the
agr inhibition tests, S. aureus strains Newman and 8325-4
were chosen.
Results are shown in Fig. 2 for the inhibition of S. aureus
Newman. They were identical for S. aureus 8325-4. The S.
epidermidis pheromone was able to completely suppress the
production of N-toxin over an 8 h incubation period already
at a concentration of 100 nM. The derivative b was equally
active, whereas the derivative a and the lactone and lactam
derivatives showed a reduced inhibiting activity. Still all of the
tested derivatives were able to inhibit the S. aureus agr system,
showing that, compared to the activating activity in S. epider-
midis, the inhibiting activity is less dependent on the original
structure of the S. epidermidis pheromone.
In none of our experiments using S. epidermidis pheromone
or its derivatives, addition of these substances to S. aureus
cultures changed the optical density of the S. aureus cultures
after the incubation period.
3.4. Phenotypic characterization of the inhibiting e¡ect on the
S. aureus agr system
The S. aureus agr system regulates the production of certain
exoproteins and surface-associated proteins. In most cases, the
exoproteins are up-regulated and the surface-associated pro-
teins are down-regulated [25]. The e¡ect of the synthetic cyclic
peptides on the production pattern of surface-associated pro-
teins and exoproteins was investigated. The synthetic cyclic
peptides were added at a concentration of 1 WM to a culture
that was inoculated by 1/100 volume of a preculture. The
cultures were incubated for 16 h. A reduction of exoprotein
production was observed. It was most pronounced with the
peptides that were also e¡ective inhibitors of N-toxin produc-
tion, i.e. the natural pheromone peptide and the modi¢ed
peptides b and a (Fig. 3A). Certain surface-associated proteins
were synthesized in higher amounts after addition of these
peptides (Fig. 3B). The same e¡ects were also observed with
the lactone- and lactam-containing peptides, but the e¡ects
were less pronounced, which is in keeping with the results
of the N-toxin test.
Immunoblot analysis of surface protein samples of S. aur-
eus Newman with antiserum raised against protein A, as an
example of a surface protein known to be down-regulated by
the agr system, showed the expected increased levels of pro-
Fig. 3. In£uence of the S. epidermidis pheromone and its derivatives
on the production of exoproteins and surface-associated proteins in
S. aureus Newman. (A) Exoproteins: basic medium was inoculated
with 1/100 volume of a preculture of S. aureus Newman. At the
same time, the pheromone or one of its derivatives was added at a
concentration of 1 WM. The peptides were dissolved in DMSO, a
control received only DMSO. Culture ¢ltrates (20 Wl) of the cultures
harvested after 16 h of growth were applied to tricine SDS-PAGE
and stained with Coomassie blue. (B) Surface-associated proteins:
pellets of the centrifuged 16 h cultures were dissolved in SDS-
PAGE loading bu¡er containing 1% SDS, boiled at 100‡C for 5 min
and applied to tricine SDS-PAGE after removal of insoluble materi-
al by centrifugation. Lanes in (A) and (B) (abbreviations of com-
pounds refer to Fig. 1): (1) compound cNH (amide derivative); (2)
compound cO (oxygen ester derivative) ; (3) compound b; (4) com-
pound cS (synthetic S. epidermidis pheromone); (5) compound a;
(6) control (with DMSO); (7) molecular weight standards.
Fig. 4. In£uence of the S. epidermidis pheromone and its derivatives
on K-toxin production and protein A production in S. aureus
strains. (A) Immunoblot with anti-K-toxin antiserum. Basic medium
was inoculated with 1/100 volume of a preculture of the respective
S. aureus strains. At the same time, the pheromone or one of its de-
rivatives was added at a concentration of 1 WM. The peptides were
dissolved in DMSO, a control received only DMSO. The culture ¢l-
trate (20 Wl) of the cultures harvested after 16 h of growth was ap-
plied to tricine SDS-PAGE. Immunoblotting and development are
described in Section 2. (B) Immunoblot with anti-protein A antise-
rum. For protein A detection, the cell pellets of the 16 h cultures
(see above) were treated with lysostaphin to release the covalently
attached protein A from the cell surface. After centrifugation, the
supernatant was applied to tricine SDS-PAGE. Immunoblotting and
development are described in Section 2. (A and B) lanes (abbrevia-
tions of compounds refer to Fig. 1): I: S. aureus Newman; II: S.
aureus RN6390; III: S. aureus sar3 ; IV: S. aureus agr3 ; (1) com-
pound a; (2) compound cS (synthetic S. epidermidis pheromone);
(3) compound b; (4) compound cO (oxygen ester derivative); (5)
compound cNH (amide derivative); (6) control (with DMSO).
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tein A production in the samples to which the thiolactone-
containing derivatives of the S. epidermidis pheromone were
added (Fig. 4B). In the control samples, no protein A was
detected. The addition of the lactone- and lactam-containing
cyclic peptides led to a detectable protein A production, but
to a lesser extent than that of the thiolactone-containing pep-
tides. Immunoblot analysis of the exoprotein samples with
antiserum raised against K-toxin, known to be up-regulated
by the agr system, gave the expected opposite results (Fig.
4A). The same results were obtained with S. aureus
RN6390, although the protein A expression in this strain
was generally lower.
The sar system has been shown to activate the agr system in
S. aureus [26]. We therefore also tested the in£uence of our
derivatives on sar3, agr3 and agr3/sar3 mutant strains to
investigate if the biological e¡ects of our pheromone deriva-
tives are exclusively mediated by their action on the agr sys-
tem and if these can be maintained in the absence of a func-
tional global regulator of superior hierarchy. In the sar3
strain, the e¡ects were similar as in the wild-type but less
pronounced, most likely because of the lacking direct e¡ect
of sar on the expression of K-toxin and protein A, which has
been reported [26,27]. Interestingly, in the sar3 strain, both
protein A and K-toxin appear mostly as proteolytic degrada-
tion products. This is probably due to the overexpression of
proteases in sar3 strains, which has been demonstrated by
Chan et al. [28]. The agr3 strain showed the expected high
expression levels of protein A and a low expression of K-toxin
(Fig. 4). Addition of the pheromone or its derivatives to this
strain or to an agr3/sar3 strain did not alter the protein A or
K-toxin expression, as expected (data not shown). The lack of
any e¡ect in an agr3 background demonstrates that our de-
rivatives exclusively act via the agr system.
The decreased production of the N-toxin and the K-toxin,
one of the most important staphylococcal virulence factors [3],
was also shown by the analysis of synergistic hemolysis [29]
on sheep blood agar plates. The control sample exhibited
pronounced synergistic hemolysis, the samples treated with
the pheromone or its derivatives showed a strongly reduced
or no synergistic hemolysis.
4. Discussion
4.1. In£uence of derivatization on biological activity,
importance of the thiolactone structure
Of all derivatives tested in this study, only the natural S.
epidermidis pheromone peptide with the correct N-terminus
and a cyclic thiolester could activate the S. epidermidis agr
system. We have previously reported that the length of the
N-terminal linear peptidyl tail is crucial for this activating
e¡ect. We now provided evidence that substitution of the
thiolester by an (oxygen-) ester or an amide also does not
lead to an activating peptide. This suggests that the interac-
tion of the peptide with the AgrC sensor kinase is extremely
speci¢c and dependent on the unusual thiolactone structure.
On the other hand, the cyclic peptides all showed a more or
less pronounced inhibitory e¡ect on the agr system of S. aur-
eus. Similar results have been achieved by Mayville at al. with
derivatives of the S. aureus AgrDII pheromone. These authors
speculate that the indispensability of the thiolactone structure
for the activating, but not inhibiting, ability suggests a possi-
ble covalent modi¢cation reaction of the AgrC sensor kinase
by the agr pheromone, probably by a trans-acylation reaction
[30]. There is no direct evidence for such a modi¢cation re-
action so far, however, our results with the S. epidermidis
pheromone and its cyclic bond type derivatives would be in
keeping with their hypothesis.
The introduction of an amide instead of the original thio-
lactone resulted in an increased chemical stability, but a
strongly reduced biological activity in the S. aureus inhibition
tests. The thiolactone-containing peptides suppressed the S.
aureus agr system more e⁄ciently in the 16 h cultures, as
shown by K-toxin, protein A and general protein levels, as
well as in the tests for synergistic hemolysis. This demon-
strates that despite the unusual reactive thiolester structure,
these compounds have an unexpectedly high stability in bac-
terial cultures.
This is the ¢rst study that provides evidence that the S.
epidermidis agr pheromone peptide acts as an inhibitor of
the S. aureus agr system and the expression of virulence fac-
tors in S. aureus. It is tempting to speculate that S. epidermidis
exploits this e¡ect to compete with S. aureus in certain envi-
ronments in the human body. S. epidermidis is the predom-
inant species on the human skin and in catheter-related infec-
tions [3]. Presumably, in cases where there is a high
population density of S. epidermidis cells, the highly active
agr system leads to an increased production of S. epidermidis
pheromone, which inhibits virulence factor expression of com-
peting S. aureus cells and thereby provides a selection advant-
age for S. epidermidis.
4.2. Development of quorum-sensing blockers of the S. aureus
agr system
Quorum-sensing blockers have been proposed as new prom-
ising agents for anti-microbial therapy. They o¡er the advant-
age of a reduced risk for the development of resistance against
the antibiotic because they only suppress the expression of
virulence factors and do not act as bacteriolytic or bacterio-
static compounds. Thus, the selection of resistant bacteria is
assumed to be minimized [2].
For many bacteria, including pathogens, quorum-sensing
systems have been characterized and, in some cases, the struc-
ture of the pheromones is known. In Gram-negative bacteria,
these are N-acylhomoserine lactones, whereas in Gram-posi-
tive bacteria, the pheromones are peptides that are often post-
translationally modi¢ed [1,31]. E¡ective synthetic quorum-
sensing blockers for Gram-positive human pathogens have
not yet been developed. There are examples of anti-infective
compounds that inhibit two-component signal transduction.
However, all these compounds also inhibit the bacterial
growth and therefore do not provide the advantage of a re-
duced risk for the development of resistance.
Mayville et al. recently synthesized thiolactone-containing
S. aureus agr pheromone peptides and derivatives. They could
show an inhibiting activity of synthetic group II pheromone
towards S. aureus cells of a di¡erent subgroup. This has also
been demonstrated in vivo, when S. aureus cells were injected
into mice together with the inhibiting pheromone, which led
to suppression of the development of skin abscesses [30].
However, as the natural S. aureus population is assumed to
be composed of members of di¡erent subgroups, treatment of
S. aureus infections with one of these pheromones should bear
the risk that the agr system including the expression of viru-
lence factors is suppressed in some of the bacterial cells, but
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activated in others, which belong to the subgroup of the ap-
plied pheromone.
We therefore tried to use the S. epidermidis pheromone as a
basis for the development of S. aureus agr quorum-sensing
blockers, as this pheromone is unlikely to activate virulence
factor expression in S. aureus pheromone subgroups of a
known or yet to be identi¢ed sequence, because, as we and
Mayville et al. [30] could show, the agr-activating e¡ect is
highly dependent on the original pheromone structure.
In our experiments, the synthetic S. epidermidis pheromone
and its derivatives inhibited the expression of the agr system
of S. aureus with a varying e⁄ciency, as was demonstrated by
the suppression of N-toxin production and by testing for syn-
ergistic hemolysis. In a 16 h culture, the substances caused a
reduction of the production of K-toxin, which is one of the
most important virulence factors of S. aureus, whereas an
increase in the production of the surface-associated protein
A was observed. Since there was no e¡ect on bacterial growth,
the S. epidermidis pheromone and its derivatives meet the
above mentioned requirements of quorum-sensing blockers.
S. epidermidis is an opportunistic pathogen and the produc-
tion of virulence factors in this strain is likely to be regulated
also by the agr system. Therefore, it was desirable to ¢nd a
derivative of the pheromone that does not activate the S.
epidermidis agr system, but is still an e¡ective inhibitor of
the S. aureus agr system. The thiolactone-containing deriva-
tive b, which lacks the N-terminal aspartate residue of the
natural pheromone, showed exactly these characteristics.
This derivative may therefore be a promising candidate as a
quorum-sensing blocker for anti-infective therapy against S.
aureus. The results also show that in general, the derivatiza-
tion of pheromones can lead to compounds with altered agr-
activating or agr-inhibiting e¡ects.
With none of our synthesized linear derivatives, we
achieved any activating or inhibiting biological e¡ect. We
therefore conclude that for the systematic construction of bio-
logically active derivatives based on the agr pheromone, a
cyclic structure is an important prerequisite.
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